American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Abdel-Wahab
    Abdel-Wahab
  10. Palomba
    Palomba

Groups

  1. Department of Medicine (3977)
  2. Hematologic Malignancies, Division of (3778)
  3. Center for Hematologic Malignancies (3661)
  4. GSK Faculty (1588)
  5. Adult Leukemia (1338)
  6. Sloan Kettering Institute Faculty (1074)
  7. Bone Marrow Transplant (975)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (954)
  9. Lymphoma (939)
  10. Tow Center for Developmental Oncology (TCDO) (881)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1242)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3977)
  2. Hematologic Malignancies, Division of (3778)
  3. Center for Hematologic Malignancies (3661)
  4. GSK Faculty (1588)
  5. Adult Leukemia (1338)
  6. Sloan Kettering Institute Faculty (1074)

More Groups

People
  1. Sergio Giralt (346)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (308)
  5. Martin Tallman (300)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (46)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5165)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5537)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarker correlates and clinical activity of cevostamab in patients (pts) with triple-class refractory multiple myeloma (MM) who have received ≥1 prior B-cell maturation antigen (BCMA)-targeted bispecific antibody (BsAb): Results from the phase I/II CAMMA 2 study
    Meeting Abstract

    Delforge, M.; Richter, J.; Cohen, Y. C.; Corradini, P.; Sborov, D. W.; Lesokhin, A. M.; Berdeja, J. G.; Gatt, M. E.; Paris, L.; Dachs, L. R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Frailty and outcomes after bispecific T-cell engager therapy for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Adegbite, B. O.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • MagnetisMM-3: Long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Prince, H. M.; Bahlis, N. J.; Rodríguez-Otero, P.; Karlin, L.; Akard, L.; Varshavsky-Yanovsky, A.; Chu, M. P.; Nagai, Y.; Vesole, D. H.; Hickman, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Expanded genome-wide association study (GWAS) identifies nine novel germline risk loci for waldenström macroglobulinemia (WM) and lymphoplasmacytic lymphoma (LPL)
    Meeting Abstract

    Park, H.; McMaster, M. L.; Hunter, Z. R.; Clay-Gilmour, A. I.; Sucheston-Campbell, L. E.; Breeze, C.; Arias, J.; Davídsson, Ó. B.; Smith-Byrne, K.; Güler, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Topic modeling of genotyping of transcriptomes reveals collaboration between BTK(C481S)-mutant and wild type cells in BTKi-resistant chronic lymphocytic leukemia
    Meeting Abstract

    Massoni-Badosa, R.; Schiffman, J. S.; Pradhan, B.; Murray, R. M.; Lipsky, A. H.; Van Egeren, D.; Luan, D.; Chen, S.; Chaligne, R.; Beattie, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment outcomes of patients treated with venetoclax-obinutuzumab therapy vs BTKi therapies in 1L CLL: An international real-world study
    Meeting Abstract

    Lamanna, N.; Brown, J. R.; Ujjani, C. S.; Eyre, T. A.; Manzoor, B.; Ghosh, N.; Roeker, L.; Davids, M. S.; Coombs, C. C.; Skarbnik, A. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genome-wide meta-analysis identifies multiple germline genetic variants associated with increased risk of follicular lymphoma
    Meeting Abstract

    Joseph, V.; Clay-Gilmour, A. I.; Park, H.; Breeze, C.; Sucheston-Campbell, L. E.; Arias, J.; Waller, R. G.; Güler, M.; Nieters, A.; Smedby, K. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prediction of clinical response by phased variants in circulating tumor DNA (ctDNA) in the VALENTINE-PTCL01 trial of patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Mehta-Shah, N.; Horwitz, S.; Zinzani, P. L.; Barta, S. K.; Yamagishi, M.; Kurtz, D. M.; Takayama, G.; Hizukuri, Y.; Feng, W.; Chang, K. C. N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save